Lantern Pharma Inc. - Common Stock (NQ:LTRN)

2.350 +0.020 (+0.86%)

Streaming Delayed Price Updated: 2:39 PM EDT, Apr 15, 2026 Add to My Watchlist

Price and Volume

Volume	147,165
Open	2.350
Bid (Size)	2.320 (100)
Ask (Size)	2.370 (600)
Prev. Close	2.330
Today's Range	2.220 - 2.384
52wk Range	1.110 - 5.744
Shares Outstanding	11,184,423
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches withZeta.ai Platform, Opens New Revenue Stream

April 14, 2026

Via Investor Brand Network

Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22

April 14, 2026

From Lantern Pharma Inc.

Via Business Wire

Performance

YTD	-24.4%	-24.4%
1 Month	-2.5%	-2.5%
3 Month	-27.9%	-27.9%
6 Month	-46.2%	-46.2%
1 Year	-33.4%	-33.4%

More News

Unusual volume stocks in Thursday's session ↗

April 02, 2026

Via Chartmill

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Host April 9 Investor Briefing Featuring Live Demo Of withZeta.ai Platform

April 02, 2026

Via Investor Brand Network

MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Host April 9 Investor Briefing Featuring Live Demo Of withZeta.ai Platform

April 02, 2026

Via Investor Brand Network

RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference

April 02, 2026

Via ACCESS Newswire

Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026

April 02, 2026

From Lantern Pharma Inc.

Via Business Wire

Which stocks have an unusual volume on Wednesday? ↗

April 01, 2026

Via Chartmill

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline With Multiple 2026 Milestones in View

March 31, 2026

Via Investor Brand Network

Discover the top movers in Tuesday's pre-market session. ↗

March 31, 2026

Via Chartmill

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

March 30, 2026

From Lantern Pharma Inc.

Via Business Wire

These stocks have an unusual volume in today's session ↗

March 30, 2026

Via Chartmill

New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)

March 28, 2026

Via ACCESS Newswire

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

March 27, 2026

From Lantern Pharma Inc.

Via Business Wire

InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives FDA Clearance For STAR-001 Pediatric CNS Cancer Trial

March 27, 2026

Via Investor Brand Network

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

March 27, 2026

From Lantern Pharma Inc.

Via Business Wire

RedChip AI Investor Conference Replays Now Available Highlighting Companies Driving Innovation Across the AI Ecosystem

March 27, 2026

Via ACCESS Newswire

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules Fourth Quarter And Fiscal Year 2025 Results Webcast

March 24, 2026

Via Investor Brand Network

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

March 23, 2026

From Lantern Pharma Inc.

Via Business Wire

New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST

March 21, 2026

Via ACCESS Newswire

RedChip Highlights Public Companies Advancing the Next Phase of AI Adoption at Virtual Investor Conference on March 19

March 16, 2026

Via ACCESS Newswire

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Present AI-Driven Neuro-Oncology Strategy at Glioblastoma Summit

February 10, 2026

Via Investor Brand Network

Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026

February 10, 2026

From Lantern Pharma Inc.

Via Business Wire

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives FDA Orphan Drug Designation For LP-284 In Soft Tissue Sarcomas

January 20, 2026

Via Investor Brand Network

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

January 20, 2026

From Lantern Pharma Inc.

Via Business Wire

Frequently Asked Questions

Is Lantern Pharma Inc. - Common Stock publicly traded?

Yes, Lantern Pharma Inc. - Common Stock is publicly traded.

What exchange does Lantern Pharma Inc. - Common Stock trade on?

Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Lantern Pharma Inc. - Common Stock?

The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market

What is the current price of Lantern Pharma Inc. - Common Stock?

The current price of Lantern Pharma Inc. - Common Stock is 2.350

When was Lantern Pharma Inc. - Common Stock last traded?

The last trade of Lantern Pharma Inc. - Common Stock was at 04/15/26 02:39 PM ET

What is the market capitalization of Lantern Pharma Inc. - Common Stock?

The market capitalization of Lantern Pharma Inc. - Common Stock is 26.28M

How many shares of Lantern Pharma Inc. - Common Stock are outstanding?

Lantern Pharma Inc. - Common Stock has 26M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.